Patient Support Services Contact Us
Image: Coherus Investors

News

09/19/22
- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis ®  (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity - - Interchangeability designation and clinical equivalence to Lucentis provides confidence that existing Lucentis
09/12/22
REDWOOD CITY, Calif. , Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24 th Annual Global Investment Conference on Wednesday, September 14 at 10:00 am ET .
08/29/22
REDWOOD CITY, Calif. , Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 24, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 234,000 shares
08/04/22
– Commercial launch of CIMERLI ™ planned for early October 2022 – – PDUFA date for toripalimab BLA is December 23, 2022 – – Commercial preparation underway for planned July 2023 launch of YUSIMRY ™ – – UDENYCA® delivers 2 nd quarter 2022 net sales of $60.1 million – – Conference call today at 5
08/02/22
- CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023 - - First CIMERLI™ product sales expected in October 2022 - - COLUMBUS AMD trial was published in the journal Ophthalmology and demonstrated the clinical equivalence of CIMERLI™
08/01/22
REDWOOD CITY, Calif. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 1, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 250,000 shares of
07/28/22
REDWOOD CITY, Calif. , July 28, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2022 financial results will be released after market close on Thursday, August 4 th , 2022. Starting at 5 p.m.
07/06/22
-   FDA has set a target action date of December 23, 2022 for the toripalimab BLA - - Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved - REDWOOD CITY, Calif. , and SHANGHAI, China , July 06, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”,
06/22/22
REDWOOD CITY, Calif. , June 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 16, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 409,000 shares of
05/11/22
- Dr. O’Donnell-Tormey is a cancer immunology key opinion leader with more than 30 years leading the Cancer Research Institute’s efforts to advance cancer immunotherapies - REDWOOD CITY, Calif. , May 11, 2022 (GLOBE NEWSWIRE) -- Coherus Biosciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced
05/10/22
REDWOOD CITY, Calif. , May 10, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in May. BofA Securities 2022 Healthcare Conference on Thursday, May 12 at 3:00 p.m.
05/05/22
– CIMERLI ™ BLA review progressing toward August 2022 action date – – Toripalimab BLA resubmission expected by mid-summer – – UDENYCA® delivers 1 st quarter 2022 net sales of $60.1 million – – 2022 R&D and SG&A expense guidance reduced by $20 million – – Conference call today at 4:30 p.m.
05/05/22
- Biotechnology Chief Financial Officer and highly regarded former healthcare investment banker brings decades of industry experience to Coherus’ immuno-oncology strategy execution - REDWOOD CITY, Calif. , May 05, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.
05/03/22
REDWOOD CITY, Calif. , May 03, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective April 27, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 240,000 shares of
05/02/22
- The CRL requests a quality process change Coherus and Junshi believe is readily addressable - -   BLA resubmission anticipated by mid-summer 2022 with expected six month FDA review timeline - - Onsite inspections in China , impeded to date by COVID-19-related travel restrictions, are required for
04/29/22
REDWOOD CITY, Calif. , April 29, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (Nasdaq: CHRS), please note in the Conference Call Information, the start time should be 4:30 p.m. ET , not 5 p.m. ET as previously stated.
04/14/22
REDWOOD CITY, Calif. , and SHANGHAI, China , April 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA")
04/08/22
- Toripalimab plus chemotherapy provided superior progression free survival, overall survival, overall response rate and duration of response compared to chemotherapy alone - SHANGHAI, China , and REDWOOD CITY, Calif. , April 08, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co.
04/05/22
REDWOOD CITY, Calif. , April 05, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective March 31, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 461,000 shares
03/29/22
— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2 billion in annual net sales from Coherus'  diversified product portfolio – REDWOOD CITY, Calif.
03/22/22
REDWOOD CITY, Calif. , March 22, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that Coherus plans to host an Analyst Day on March 29, 2022 at 9:30 a.m. ET in New York City . Coherus executives and scientists will provide updates on the preparation
03/15/22
- Dr. Dias is a biotech and pharma industry executive with more than 20 years of global experience launching oncology products - REDWOOD CITY, Calif. , March 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Rosh Dias , MD, MRCP, has
03/15/22
– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone   – - Data support the use of toripalimab with chemotherapy as first-line treatment for advanced NSCLC patients without
03/04/22
REDWOOD CITY, Calif. , March 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the following investor conferences in March. 42 nd Annual Cowen Health Care Conference on Wednesday, March 9 at 10:30 a.m.
03/04/22
- Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with advanced ESCC - - PFS and OS benefits were observed across all PD-L1 expression subgroups, including in patients with  low PD-L1 expression - REDWOOD CITY, Calif.
02/17/22
– YUSIMRY ™ (adalimumab-aqvh), Coherus’ second product, approved by FDA on December 17, 2021 – – BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI ™ (ranibizumab-ranq) – – New FDA filings expected in 2022 for UDENYCA ® on-body injector and additional toripalimab indications – –
02/15/22
REDWOOD CITY, Calif. , Feb. 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Paul Reider has been named Chief Commercial Officer. Mr. Reider previously held the position of Executive Vice President of Commercial Operations and Market
02/14/22
REDWOOD CITY, Calif. , Feb. 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective Feb. 9, 2022 , the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 236,500 shares of
02/11/22
REDWOOD CITY, Calif. , Feb. 11, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus”, Nasdaq: CHRS), today announced that its fourth quarter and full year 2021 financial results will be released after market close on Thursday, February 17, 2022. Starting at 5 p.m.
02/07/22
Jim Healy, Director since 2014, steps down from the Coherus board REDWOOD CITY, Calif. , Feb. 07, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences , Inc. (“Coherus” or the “Company”, Nasdaq: CHRS) today announced the appointment of board-certified oncologist and seasoned healthcare executive Lee N.
01/10/22
•  Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor types •  Combinations of PD-1 + TIGIT inhibitors have potential to expand checkpoint inhibitor utilization to new tumors and lines of therapy REDWOOD CITY, Calif.
01/07/22
Balance sheet strengthened to support commercial launches of as many as five new products in 2022 and 2023 REDWOOD CITY, Calif. , Jan. 07, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) today announced that it has entered into a loan agreement
01/04/22
REDWOOD CITY, Calif. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9 a.m. EST / 6 a.m. PST .